CD133 in combination with ALDH1 can be used as putative cancer stem cell markers in bladder carcinomas

  • سال انتشار: 1392
  • محل انتشار: پانزدهمین همایش سالانه انجمن علمی آسیب شناسی ایران
  • کد COI اختصاصی: ACPLMED15_083
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 475
دانلود فایل این مقاله

نویسندگان

Elmira Gheytanchi

Oncopathology Research Centre (OPRC), Iran University of Medical Sciences (IUMS), Tehran, Iran

Hossein Keimousi

Department of Pathology, Iran University of Medical Sciences (IUMS), Tehran, Iran

Zahra Madjd

Oncopathology Research Centre (OPRC), Iran University of Medical Sciences (IUMS), Tehran, Iran

Mojgan Asgari

Oncopathology Research Centre (OPRC), Iran University of Medical Sciences (IUMS), Tehran, Iran- Department of Pathology, Hasheminejad Kidney Center, Iran University of Medical Sciences (IUMS),Tehran, Iran

چکیده

Introduction:In this study the clinical significance of CD133 expression as CSC marker in combinationwith other putative marker (ALDH1) in bladder cancer was evaluated.Material & Method:A series of bladder tumors including 107(62%) high grade and 66(38%) low grade whichwere included in tissue microarray (TMA) were examined for the expression of CD133 andALDH1 using immunohistochemistry. The correlation of expression of these markers withclinicopathological parameters was also evaluated.Results:Of 161stained cores, elevated level of CD133 and ALDH1 was observed in 32% (52) and 15% (25) of tumours, respectively. The average intensity of CD133 expression (mean = 2.17)was higher than ALDH1 expression (mean = 0.7). The mean H-score of CD133 and ALDH1was 147and 8.4, respectively. The expression of CD133 was significantly associated withtumor size (P=0.049). The combination of CD133/ALDH1 H-score was associated withhistologic grade (P=0.000), laminapropria involvement, muscular invasion and recurrence (allP < 0.05). The intensity of CD133/ALDH1expresssin was related to histologic grade,mascular invasion, tumor size (all P=0.000) and lamina propria involvement (p=0.008).Conclusion:Our study showed that the ALDH1+ population is a subset of the CD133+ bladder cancercells. The ALDH1+ cancer cells, therefore, accounted for a fraction of CD133+ tumor cellpopulation. CD133 in combination with other putative stem cell marker, ALDH1can be avaluable tool for the study of urothelial CSCs. Indeed, the CD133+/ALDH1+ phenotypeprovide a useful combined marker to predict clinical outcome and act as novel therapeutictarget for treatment of the patients with urothelial carcinomas.

کلیدواژه ها

CD133, ALDH1, CSCs, Bladder Carcinoma

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.